POU4F1 promotes the resistance of melanoma to BRAF inhibitors through MEK/ERK pathway activation and MITF up-regulation

BRAF inhibitors (BRAFi) have shown remarkable clinical efficacy in the treatment of melanoma with BRAF mutation. Nevertheless, most patients end up with the development of BRAFi resistance, which strongly limits the clinical application of these agents. POU4F1 is a stem cell-associated transcription...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Cell Death Dis
Главные авторы: Liu, Lin, Yue, Qiao, Ma, Jingjing, Liu, Yu, Zhao, Tao, Guo, Weinan, Zhu, Guannan, Guo, Sen, Wang, Shiyu, Gao, Tianwen, Li, Chunying, Shi, Qiong
Формат: Artigo
Язык:Inglês
Опубликовано: Nature Publishing Group UK 2020
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7293281/
https://ncbi.nlm.nih.gov/pubmed/32532957
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41419-020-2662-2
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы